Cargando…

636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)

BACKGROUND: Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. A dengue vaccine that can be given to both seronegative and seropositive populations remains an important unmet medical need. V181 is an investigational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, Kevin, Rupp, Richard E, Morales-Ramirez, Javier O, Diaz-Perez, Clemente, Andrews, Charles P, Lee, Andrew W, Finn, Tyler S, Cox, Kara, Russell, Amy Falk, Schaller, Margaret M, Martin, Jason C, Hyatt, Donna M, Gozlan-Kelner, Sabrina, Bili, Androniki, Coller, Beth-Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643940/ http://dx.doi.org/10.1093/ofid/ofab466.833

Ejemplares similares

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults
por: Russell, Kevin L., et al.
Publicado: (2022)

636. Immunogenicity, Safety and Tolerability of a Booster Dose of Clostridium difficile Vaccine and 4 Year Antibody Persistence
por: Remich, Shon A, et al.
Publicado: (2020)

Estudios de pequeña velocidad Op. 636
por: Czerny, Carl, 1791-1857
Publicado: (1994)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

24 Studi della piccola velocita Op. 636 : per pianoforte
por: Czerny, Karl, 1791-1857
Publicado: (1949)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy
por: Shirai, Shimpei, et al.
Publicado: (2018)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
por: Greenberg, David P., et al.
Publicado: (2017)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

FRI636 Sleep Architecture In Diabetic Patients With Sleep Apnea On Metformin
por: Varma, Madhu, et al.
Publicado: (2023)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

636. The Hepcidin-25 and Iron Kinetics During the Acute Phase of Systemic Infection
por: Moro, Hiroshi, et al.
Publicado: (2018)

636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States
por: Iovleva, Alina, et al.
Publicado: (2019)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
por: Batmunkh, Tsetsegsaihan, et al.
Publicado: (2020)

Interleukin-6 (-636 C/G) Gene Polymorphism in Korean Children With Kawasaki Disease
por: Ahn, Hye Mi, et al.
Publicado: (2011)

The Influence of the I7 Experimental Magnets on the Beams, Runs 631, 636, 646, 662
por: Hoffmann, H
Publicado: (1976)

636. Epidemiology and Outcome Among the Elderly Hospitalized Patients with Respiratory Syncytial Virus Infections
por: Bhargava, Ashish, et al.
Publicado: (2023)

Aspirin Use in Rheumatoid Arthritis Patients with Increased Risk of Cardiovascular Disease
por: Cote, Jonida K., et al.
Publicado: (2013)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
por: Langley, Joanne M., et al.
Publicado: (2013)

Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years
por: Soybilgic, Arzu, et al.
Publicado: (2013)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency
por: Kostinova, Aristitsa Mikhailovna, et al.
Publicado: (2020)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
por: Vesikari, Timo, et al.
Publicado: (2019)

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study
por: Grein, Ingrid Herta Rotstein, et al.
Publicado: (2020)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Nutrient Intake in Italian Infants and Toddlers from North and South Italy: The Nutrintake 636 Study
por: Zuccotti, Gian Vincenzo, et al.
Publicado: (2014)

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir
por: Morishita, Asahiro, et al.
Publicado: (2018)

miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis
por: Bardin, Pauline, et al.
Publicado: (2019)

SAT636 Obesity And Aging Interactions Modify The Breast Tissue Microbiome Influencing Cancer Risk
por: Iyengar, Neil M, et al.
Publicado: (2023)

THU636 Prevalence Of Metabolic Syndrome In A Sample Of Hispanic Patients With Polycystic Ovary Syndrome
por: Arroyo, Isabel C, et al.
Publicado: (2023)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
por: Kostinov, Mikhail P., et al.
Publicado: (2020)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_k2ocfkbcn1evtn88ukeh18jdf7